# Title

 Food and Drugs. PART 600â€”BIOLOGICAL PRODUCTS: GENERAL


# ID

 CFR-2018-title21-vol7.Pt. 600


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'exceeds', 'within', 'more than', 'not to exceed', 'no later than', 'later than', 'after', 'minimum', 'at least', 'no less than', 'prior to', 'greater', 'no more than']                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Duration    | ['30.0 day', '6 month', '2.0 hour', '6.0 week', '15.0 day', '6.0 month', '2.0 year', '60.0 day', '4.0 week', '5.0 day', '2.0 week', '5 year', '45.0 day', '10.0 year', '7.0 day', '3.0 year', '1 quarter', '20.0 minute']                                                                                                                                                                                                                                                                                                                                                                                      |
| Condition   | ['until', 'unless', 'not subject to', 'where', 'as soon as', 'subject to', 'when', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Entities    | ['United States', 'Research, ATTN', 'ICSRs', 'Process', 'Obtain', 'Purity', 'Biological', 'Written', 'Unexpected', 'Serious', 'Blood', 'Manufacturer', 'Street', 'Equipment', 'Viable', 'Work', 'Environmental', 'Animal', 'Individual', 'G112', 'G707', 'Plasma', 'Food', 'Followup', 'Live', 'Unique', 'Important', 'Distribution', 'Columbia', 'Laboratory', 'Surveillance, Office', 'Health', 'Apparatus', 'Casual', 'Cage', 'Adverse', 'G406A', 'Significant', 'Rm', 'Beltsville, MD', 'Research', 'U.S', 'Appropriate', 'Life', 'Surveillance', 'Retention', 'Physical', 'Due', 'Disability', 'Vaccine'] |
| Date        | ['136-09-20', '1944-07-01']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                               |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------------------|
| within        | animals used, and personnel engaged by a manufacturer within a particular area designated by an address adequate                      |
| before        | application or supplement that must be satisfactorily addressed before  it can be approved.                                           |
| before        | a complete response letter, but which was withdrawn before approval and later submitted again, is not a                               |
| prior to      | outer clothing, including shoes, or wear protective covering prior to  entering such areas.                                           |
| after         | may not enter a live vaccine processing area after having worked with other infectious agents in any                                  |
| before        | be replaced or covered by suitable laboratory clothing before  entering a live vaccine processing unit.                               |
| minimum       | cleaning and to keep air-borne contaminants at a minimum .                                                                            |
| prior to      | other purposes, they shall be cleaned and prepared prior to  use for sterile operations.                                              |
| within        | and warm rooms shall be maintained at temperatures within applicable ranges and shall be free of extraneous                           |
| no less than  | The effectiveness of the sterilization procedure shall be  no less than that achieved by an attained temperature of 121.5             |
| before        | provided the space is thoroughly cleaned and disinfected before  the manufacture of products is resumed.                              |
| before        | the purposes of the test and only immediately before use for such purposes: Provided, That (i) the                                    |
| within        | to prevent contamination of other products and areas within  the site.                                                                |
| within        | or decontamination of the spore-forming microorganisms on and within manufacturing equipment, facilities, and ancillary room items as |
| after         | during manufacturing operations and in the manufacturing area after  completion of cleaning and decontamination.                      |
| within        | contamination of other products and other manufacturing areas within  the building.                                                   |
| within        | contamination of other products and other manufacturing areas within  the building.                                                   |
| within        | cross contamination of other products and manufacturing areas within the building, including the introduction of live vaccine         |
| at least      | inspection and preliminary quarantine for a period of at least 7 days before use, or as otherwise provided                            |
| before        | for a period of at least 7 days before  use, or as otherwise provided in this subchapter.                                             |
| at least      | of vaccine shall be maintained in quarantine for at least 6 weeks prior to use, except when otherwise                                 |
| prior to      | maintained in quarantine for at least 6 weeks prior to  use, except when otherwise provided in this part.                             |
| within        | the start of the quarantine period and again within 2 weeks prior to use shall be used                                                |
| prior to      | the quarantine period and again within 2 weeks prior to use shall be used in the manufacture of                                       |
| no more than  | except the front which shall be screened, with no more than  two monkeys housed in one cage.                                          |
| prior to      | free of contaminants, as determined by appropriate tests prior to  use.                                                               |
| within        | Injections shall not be made into horses  within  6 inches of bleeding site.                                                          |
| within        | shall not be used if it was drawn within 5 days of injecting the animals with viable                                                  |
| after         | integrity of the product during the dating period. after                                                                              |
| after         | As soon as possible  after filling final containers shall be labeled as prescribed                                                    |
| at least      | sealed receptacle labeled both inside and outside with at least the name of the product, the lot number,                              |
| no less than  | The retention period shall be  no less than five years after the records of manufacture have                                          |
| after         | period shall be no less than five years after the records of manufacture have been completed or                                       |
| after         | period shall be no less than five years after the records of manufacture have been completed or                                       |
| at least      | Manufacturers shall retain for a period of  at least 6 months after the expiration date, unless a                                     |
| after         | for a period of at least 6 months after the expiration date, unless a different time period                                           |
| at least      | from bulk and final containers, provided they include at least one final container as a final package, or                             |
| after         | this section, if a biological product deviation occurs after the manufacture of that Source Plasma or any                             |
| not to exceed | possible but you must report at a date not to exceed 45-calendar days from the date you, your agent,                                  |
| at least      | establishment and its additional location(s) shall be made at least  once every 2 years.                                              |
| greater       | labeling, but differ from the event because of greater  severity or specificity.                                                      |
| greater       | hepatic necrosis would be unexpected (by virtue of greater severity) if the labeling only referred to elevated                        |
| greater       | cerebral vasculitis would be unexpected (by virtue of greater specificity) if the labeling only listed cerebral vascular              |
| no later than | foreign or domestic, as soon as possible but no later than 15 calendar days from initial receipt of the                               |
| within        | 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information                           |
| within        | any appropriate means, each report to the applicant within 5 calendar days of initial receipt of the                                  |
| within        | The applicant must submit each quarterly report  within 30 days of the close of the quarter                                           |
| within        | The applicant must submit each quarterly report  within 30 days of the close of the quarter                                           |
| within        | (either individually or in one or more batches) within the timeframe specified in paragraph (c)(2)(i) of this                         |
| after         | or nonprescription product; (vii) Whether adverse experience abated after product use stopped or dose reduced; (viii) Whether         |
| after         | or nonprescription product; (vii) Whether adverse experience abated after product use stopped or dose reduced; (viii) Whether         |
| after         | this chapter); (vii) Whether the adverse experience abated after product use stopped or dose reduced; (viii) Whether                  |
| after         | this chapter); (vii) Whether the adverse experience abated after product use stopped or dose reduced; (viii) Whether                  |
| prior to      | (4) Vaccine(s) administered in the 4 weeks  prior to  the vaccination date.                                                           |
| more than     | If a report refers to  more than one biological product marketed by an applicant, the                                                 |
| at least      | a permanent discontinuance or interruption in manufacturing occurs. at least                                                          |
| prior to      | review, and archive: (1) At least 6 months prior to the date of the permanent discontinuance or interruption                          |
| later than    | soon as practicable thereafter, but in no case later than 5 business days after such a permanent discontinuance                       |
| after         | months in advance, as soon as practicable there after , but in no case later than 5                                                   |
| later than    | (1) Not  later than 30 calendar days after the issuance of such                                                                       |
| after         | (1) Not later than 30 calendar days  after the issuance of such a letter, the applicant                                               |
| later than    | (1) Not  later than 30 calendar days after the issuance of such                                                                       |
| after         | (1) Not later than 30 calendar days  after the issuance of such a letter, the applicant                                               |
| after         | (1) Not later than 30 calendar days  after the issuance of such a letter, the applicant                                               |
| within        | demand or projected demand for the biological product within the United States exceeds the supply of the                              |
| exceeds       | for the biological product within the United States exceeds  the supply of the biological product.                                    |
| more than     | a biological product by a manufacturer that is more than negligible and affects the ability of the manufacturer                       |


## Duration

| Duration    | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20.0 minute | The effectiveness of the sterilization procedure shall be no less than that achieved by an attained temperature of 121.5 &#176;C maintained for 20 minutes by saturated steam or by an attained temperature of 170 &#176;C maintained for 2 hours with dry heat.                                                                                                                                                                                               |
| 2.0 hour    | The effectiveness of the sterilization procedure shall be no less than that achieved by an attained temperature of 121.5 &#176;C maintained for 20 minutes by saturated steam or by an attained temperature of 170 &#176;C maintained for 2 hours with dry heat.                                                                                                                                                                                               |
| 7.0 day     | No animal shall be used in processing unless kept under competent daily inspection and preliminary quarantine for a period of at least 7 days before use, or as otherwise provided in this subchapter.                                                                                                                                                                                                                                                         |
| 6.0 week    | In addition to observing the pertinent general quarantine requirements, monkeys used as a source of tissue in the manufacture of vaccine shall be maintained in quarantine for at least 6 weeks prior to use, except when otherwise provided in this part.                                                                                                                                                                                                     |
| 2.0 week    | Only monkeys that have reacted negatively to tuberculin at the start of the quarantine period and again within 2 weeks prior to use shall be used in the manufacture of vaccine.                                                                                                                                                                                                                                                                               |
| 5.0 day     | Blood shall not be used if it was drawn within 5 days of injecting the animals with viable microorganisms.                                                                                                                                                                                                                                                                                                                                                     |
| 5 year      | The retention period shall be no less than five years after the records of manufacture have been completed or six months after the latest expiration date for the individual product, whichever represents a later date.                                                                                                                                                                                                                                       |
| 6 month     | The retention period shall be no less than five years after the records of manufacture have been completed or six months after the latest expiration date for the individual product, whichever represents a later date.                                                                                                                                                                                                                                       |
| 6.0 month   | Manufacturers shall retain for a period of at least 6 months after the expiration date, unless a different time period is specified in additional standards, a quantity of representative material of each lot of each product, sufficient for examination and testing for safety and potency, except Whole Blood, Cryoprecipitated AHF, Platelets, Red Blood Cells, Plasma, and Source Plasma and Allergenic Products prepared to a physician's prescription. |
| 45.0 day    | You should report a biological product deviation as soon as possible but you must report at a date not to exceed 45-calendar days from the date you, your agent, or another person who performs a manufacturing, holding, or distribution step under your control, acquire information reasonably suggesting that a reportable event has occurred.                                                                                                             |
| 2.0 year    | An inspection of each licensed establishment and its additional location(s) shall be made at least once every 2 years.                                                                                                                                                                                                                                                                                                                                         |
| 15.0 day    | The applicant must submit to FDA postmarketing 15-day Alert reports and periodic safety reports pertaining to its biological product as described in this section.                                                                                                                                                                                                                                                                                             |
| 15.0 day    | (1)(i) Postmarketing 15-day &#8220;Alert reports&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                       |
| 15.0 day    | The applicant must report each adverse experience that is both serious and unexpected, whether foreign or domestic, as soon as possible but no later than 15 calendar days from initial receipt of the information by the applicant.                                                                                                                                                                                                                           |
| 15.0 day    | (ii) Postmarketing 15-day &#8220;Alert reports&#8221;&#8212;followup.                                                                                                                                                                                                                                                                                                                                                                                          |
| 15.0 day    | The applicant must promptly investigate all adverse experiences that are the subject of these postmarketing 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information or as requested by FDA.                                                                                                                                                                                                                |
| 15.0 day    | The applicant must promptly investigate all adverse experiences that are the subject of these postmarketing 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information or as requested by FDA.                                                                                                                                                                                                                |
| 15.0 day    | The requirements of paragraphs (c)(1)(i) and (c)(1)(ii) of this section, concerning the submission of postmarketing 15-day Alert reports, also apply to any person whose name appears on the label of a licensed biological product as a manufacturer, packer, distributor, shared manufacturer, joint manufacturer, or any other participant involved in divided manufacturing.                                                                               |
| 5.0 day     | If a person elects to submit adverse experience reports to the applicant rather than to FDA, the person must submit, by any appropriate means, each report to the applicant within 5 calendar days of initial receipt of the information by the person, and the applicant must then comply with the requirements of this section.                                                                                                                              |
| 3.0 year    | (i) The applicant must report each adverse experience not reported under paragraph (c)(1)(i) of this section at quarterly intervals, for 3 years from the date of issuance of the biologics license, and then at annual intervals.                                                                                                                                                                                                                             |
| 30.0 day    | The applicant must submit each quarterly report within 30 days of the close of the quarter (the first quarter beginning on the date of issuance of the biologics license) and each annual report within 60 days of the anniversary date of the issuance of the biologics license.                                                                                                                                                                              |
| 1 quarter   | The applicant must submit each quarterly report within 30 days of the close of the quarter (the first quarter beginning on the date of issuance of the biologics license) and each annual report within 60 days of the anniversary date of the issuance of the biologics license.                                                                                                                                                                              |
| 60.0 day    | The applicant must submit each quarterly report within 30 days of the close of the quarter (the first quarter beginning on the date of issuance of the biologics license) and each annual report within 60 days of the anniversary date of the issuance of the biologics license.                                                                                                                                                                              |
| 15.0 day    | (1) A narrative summary and analysis of the information in the report;                                                                                                                                                                                                                                                                                                                                                                                         |
|             |               (2) An analysis of the 15-day Alert reports submitted during the reporting interval (all 15-day Alert reports being appropriately referenced by the applicant's patient identification code for nonvaccine biological product reports or by the unique case identification number for vaccine reports, adverse reaction term(s), and date of submission to FDA);                                                                                 |
|             |               (3) A history of actions taken since the last report because of adverse experiences (for example, labeling changes or studies initiated);                                                                                                                                                                                                                                                                                                        |
|             |               (4) An index consisting of a line listing of the applicant's patient identification code for nonvaccine biological product reports or by the unique case identification number for vaccine reports and adverse reaction term(s) for ICSRs submitted under paragraph (c)(2)(ii)(B) of this section; and                                                                                                                                           |
|             |               (B) ICSRs for serious, expected and, nonserious adverse experiences.                                                                                                                                                                                                                                                                                                                                                                             |
| 15.0 day    | (1) A narrative summary and analysis of the information in the report;                                                                                                                                                                                                                                                                                                                                                                                         |
|             |               (2) An analysis of the 15-day Alert reports submitted during the reporting interval (all 15-day Alert reports being appropriately referenced by the applicant's patient identification code for nonvaccine biological product reports or by the unique case identification number for vaccine reports, adverse reaction term(s), and date of submission to FDA);                                                                                 |
|             |               (3) A history of actions taken since the last report because of adverse experiences (for example, labeling changes or studies initiated);                                                                                                                                                                                                                                                                                                        |
|             |               (4) An index consisting of a line listing of the applicant's patient identification code for nonvaccine biological product reports or by the unique case identification number for vaccine reports and adverse reaction term(s) for ICSRs submitted under paragraph (c)(2)(ii)(B) of this section; and                                                                                                                                           |
|             |               (B) ICSRs for serious, expected and, nonserious adverse experiences.                                                                                                                                                                                                                                                                                                                                                                             |
| 15.0 day    | (iii) Periodic reporting, except for information regarding 15-day Alert reports, does not apply to adverse experience information obtained from postmarketing studies (whether or not conducted under an investigational new drug application), from reports in the scientific literature, and from foreign marketing experience.                                                                                                                              |
| 15.0 day    | A 15-day Alert report based on information in the scientific literature must be accompanied by a copy of the published article.                                                                                                                                                                                                                                                                                                                                |
| 15.0 day    | The 15-day Alert reporting requirements in paragraph (c)(1)(i) of this section (i.e., serious, unexpected adverse experiences) apply only to reports found in scientific and medical journals either as case reports or as the result of a formal clinical trial.                                                                                                                                                                                              |
| 15.0 day    | Applicants are not required to submit a 15-day Alert report under paragraph (c) of this section for an adverse experience obtained from a postmarketing clinical study (whether or not conducted under a biological investigational new drug application) unless the applicant concludes that there is a reasonable possibility that the product caused the adverse experience.                                                                                |
| 15.0 day    | (i) Applicant name and contact office address;                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (ii) Telephone number;                                                                                                                                                                                                                                                                                                                                                                                                                           |
|             |               (iii) Report source, such as spontaneous, literature, or study;                                                                                                                                                                                                                                                                                                                                                                                  |
|             |               (iv) Date the report was received by applicant;                                                                                                                                                                                                                                                                                                                                                                                                  |
|             |               (v) Application number and type;                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (vi) Whether the ICSR is a 15-day &#8220;Alert report&#8221;;                                                                                                                                                                                                                                                                                                                                                                                    |
|             |               (vii) Whether the ICSR is an initial report or followup report; and                                                                                                                                                                                                                                                                                                                                                                              |
|             |               (viii) Unique case identification number, which must be the same in the initial report and any subsequent followup report(s).                                                                                                                                                                                                                                                                                                                    |
| 4.0 week    | (4) Vaccine(s) administered in the 4 weeks prior to the vaccination date.                                                                                                                                                                                                                                                                                                                                                                                      |
| 15.0 day    | (i) Applicant name and contact office address;                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (ii) Telephone number;                                                                                                                                                                                                                                                                                                                                                                                                                           |
|             |               (iii) Report source, such as spontaneous, literature, or study;                                                                                                                                                                                                                                                                                                                                                                                  |
|             |               (iv) Date received by applicant;                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (v) Application number and type;                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (vi) Whether the ICSR is a 15-day &#8220;Alert report&#8221;;                                                                                                                                                                                                                                                                                                                                                                                    |
|             |               (vii) Whether the ICSR is an initial report or followup report; and                                                                                                                                                                                                                                                                                                                                                                              |
|             |               (viii) Unique case identification number, which must be the same in the initial report and any subsequent followup report(s).                                                                                                                                                                                                                                                                                                                    |
| 10.0 year   | The applicant must maintain for a period of 10 years records of all adverse experiences known to the applicant, including raw data and any correspondence relating to the adverse experiences.                                                                                                                                                                                                                                                                 |
| 6.0 month   | The interval between distribution reports must be 6 months.                                                                                                                                                                                                                                                                                                                                                                                                    |
| 6.0 month   | Upon written notice, FDA may require that the applicant submit distribution reports under this section at times other than every 6 months.                                                                                                                                                                                                                                                                                                                     |
| 6.0 month   | Notifications required by paragraph (a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                         |
|             |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                     |
|             |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after such a permanent discontinuance or interruption in manufacturing occurs.                                                                                                            |
| 6.0 month   | Notifications required by paragraph (a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                         |
|             |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                     |
|             |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after such a permanent discontinuance or interruption in manufacturing occurs.                                                                                                            |
| 6.0 month   | Notifications required by paragraph (a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                         |
|             |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                     |
|             |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after such a permanent discontinuance or interruption in manufacturing occurs.                                                                                                            |
| 5.0 day     | Notifications required by paragraph (a) of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:                                                                                                                                                                                                                                                                                                         |
|             |               (1) At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or                                                                                                                                                                                                                                                                                                                                     |
|             |               (2) If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after such a permanent discontinuance or interruption in manufacturing occurs.                                                                                                            |
| 30.0 day    | (1) Not later than 30 calendar days after the issuance of such a letter, the applicant must submit to FDA a written response setting forth the basis for noncompliance and providing the required notification under paragraph (a) of this section and including the information required under paragraph (c) of this section; and                                                                                                                             |
|             |               (2) Not later than 45 calendar days after the issuance of a letter under this paragraph, FDA will make the letter and the applicant's response to the letter public, unless, after review of the applicant's response, FDA determines that the applicant had a reasonable basis for not notifying FDA as required under paragraph (a) of this section.                                                                                           |
| 45.0 day    | (1) Not later than 30 calendar days after the issuance of such a letter, the applicant must submit to FDA a written response setting forth the basis for noncompliance and providing the required notification under paragraph (a) of this section and including the information required under paragraph (c) of this section; and                                                                                                                             |
|             |               (2) Not later than 45 calendar days after the issuance of a letter under this paragraph, FDA will make the letter and the applicant's response to the letter public, unless, after review of the applicant's response, FDA determines that the applicant had a reasonable basis for not notifying FDA as required under paragraph (a) of this section.                                                                                           |


## Condition

| Condition      | Context                                                                                                                              |
|:---------------|:-------------------------------------------------------------------------------------------------------------------------------------|
| when           | A cover letter should not be included  when submitting the protocol with the sample unless it                                        |
| unless         | included when submitting the protocol with the sample unless it contains pertinent information affecting the release of              |
| if             | A product is analogous: (i) To a virus if prepared from or with a virus or agent                                                     |
| if             | (ii) To a therapeutic serum,  if composed of whole blood or plasma or containing                                                     |
| if             | (iii) To a toxin or antitoxin,  if intended, irrespective of its source of origin, to                                                |
| when           | mode of administration or application recommended, including use when intended through administration or application to a person     |
| if             | also any other use for purposes of diagnosis if the diagnostic substance so used is prepared from                                    |
| where          | date means the calendar month and year, and where applicable, the day and hour, that the dating                                      |
| when           | persons affected, directly or indirectly, by a product when prudently administered, taking into consideration the character of       |
| subject to     | entity engaged in the manufacture of a product subject to license under the act; &#8220;Manufacturer&#8221; also includes any        |
| where          | entity who is an applicant for a license where the applicant assumes responsibility for compliance with the                          |
| subject to     | other than by sale at retail, of products subject to  license.                                                                       |
| where          | a product shall be excluded from the room where  the manufacture of a product is in progress.                                        |
| where          | or animal quarters, shall be excluded from areas where other products are manufactured, or such persons shall                        |
| when           | shall be allowed in live vaccine processing areas when  active work is in progress.                                                  |
| where          | All rooms and work areas  where products are manufactured or stored shall be kept                                                    |
| where          | Filling rooms, and other rooms  where open, sterile operations are conducted, shall be adequate                                      |
| where          | designed and constructed to permit thorough cleaning and, where  possible, inspection for cleanliness.                               |
| unless         | sterility is a factor, equipment shall be sterile, unless sterility of the product is assured by subsequent                          |
| if             | separate dedicated building or by using process containment if  manufacturing is conducted in a multiproduct manufacturing building. |
| where          | All product and personnel movement between the area  where the spore-forming microorganisms are manufactured and other manufacturing |
| if             | manufacturing area for subsequent manufacture of other products. if                                                                  |
| if             | using procedural controls, and where necessary, process containment. if                                                              |
| where          | manufacturing building or area, using procedural controls, and where  necessary, process containment.                                |
| unless         | Process containment is deemed to be necessary  unless procedural controls are sufficient to prevent cross contamination              |
| until          | animals and shall not be used for production until  recovery is complete.                                                            |
| unless         | No animal shall be used in processing  unless kept under competent daily inspection and preliminary quarantine                       |
| when           | at least 6 weeks prior to use, except when  otherwise provided in this part.                                                         |
| when           | Viable antigens,  when so used, shall be free of contaminants, as                                                                    |
| if             | Blood shall not be used  if it was drawn within 5 days of injecting                                                                  |
| when           | Animals shall not be bled for manufacturing purposes  when  they have an intercurrent disease.                                       |
| unless         | at least 6 months after the expiration date, unless a different time period is specified in additional                               |
| when           | the Director, Center for Drug Evaluation and Research, when  the lot yields relatively few final containers and                      |
| when           | the Director, Center for Drug Evaluation and Research, when  the lot yields relatively few final containers and                      |
| when           | license and who had control over the product when  the deviation occurred, must report under this section.                           |
| not subject to | manufacture only in vitro diagnostic products that are not subject to licensing under section 351 of the Public Health               |
| if             | must report: (A) Under &#167;&#8201;606.171 of this chapter, if a biological product deviation occurs during the manufacture         |
| if             | must report: (A) Under &#167;&#8201;606.171 of this chapter, if a biological product deviation occurs during the manufacture         |
| if             | holding or distribution, of a licensed biological product, if that event meets all the following criteria: (1)                       |
| when           | (c) When do I report under this section? when                                                                                        |
| as soon as     | You should report a biological product deviation  as soon as possible but you must report at a date                                  |
| where          | (e) Where do I report under this section? where                                                                                      |
| if             | you make a paper filing, you should ident if y on the envelope that a biological product                                             |
| until          | license application is pending need not be made until the establishment is in operation and is manufacturing                         |
| until          | the original license, no reinspection need be made until assurance has been received that the faulty conditions                      |
| unless         | and shall be made during regular business hours unless  otherwise directed.                                                          |
| when           | hospitalization may be considered a serious adverse experience when , based upon appropriate medical judgment, they may              |
| if             | would be unexpected (by virtue of greater severity) if the labeling only referred to elevated hepatic enzymes                        |
| if             | would be unexpected (by virtue of greater spec if icity)                                                                             |
| subject to     | Any person  subject to the reporting requirements under paragraph (c) of this                                                        |
| as soon as     | both serious and unexpected, whether foreign or domestic, as soon as possible but no later than 15 calendar days                     |
| unless         | conducted under a biological investigational new drug application) unless the applicant concludes that there is a reasonable         |
| if             | is a health care professional; and (iii) Occupation, if  a health care professional.                                                 |
| if             | is a health care professional; and (iii) Occupation, if  a health care professional.                                                 |
| where          | (6) Facility and personnel  where  vaccine was administered.                                                                         |
| where          | vaccine; (ii) Name of responsible physician at facility where vaccine was administered; and (iii) Name, address (including           |
| where          | vaccine; (ii) Name of responsible physician at facility where vaccine was administered; and (iii) Name, address (including           |
| subject to     | (2) Persons  subject to the requirements of paragraph (c) of this section                                                            |
| if             | any adverse experience that occurred in clinical trials if they were previously submitted as part of the                             |
| when           | as part of the initial reporter information, even when  the reporter is the patient.                                                 |
| subject to     | These products are  subject to  the reporting requirements for devices.                                                              |
| if             | Not if ications required by paragraph (a) of this section                                                                            |
| as soon as     | was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than                     |
| subject to     | information: (1) The name of the biological product subject to the notification, including the National Drug Code for                |
| if             | Food, Drug, and Cosmetic Act (21 U.S.C. 356c(c)) if FDA determines that disclosure of such information would                         |
| unless         | and the applicant's response to the letter public, unless , after review of the applicant's response, FDA                            |
| when           | shortage or shortage means a period of time when the demand or projected demand for the biological                                   |
| if             | (b) FDA may grant a waiver  if it finds one of the following: (1) The                                                                |


## Entities

| Entities             | Context                                                                                                                          |
|:---------------------|:---------------------------------------------------------------------------------------------------------------------------------|
| Food                 | Food  and Drugs.                                                                                                                 |
| Research             | regulated by the Center for Biologics Evaluation and Research  (CBER).                                                           |
| Research             | and Drug Administration, Center for Biologics Evaluation and Research , Document Control Center, 10903 New Hampshire Ave.,       |
| Rm                   | 71,  Rm .                                                                                                                        |
| G112                 | G112 , Silver Spring, MD 20993-0002.                                                                                             |
| Biological           | Biological products samples must not be sent to this                                                                             |
| Research             | regulated by the Center for Drug Evaluation and Research  (CDER).                                                                |
| Research             | Central Document Room, Center for Drug Evaluation and Research , Food and Drug Administration, 5901B Ammendale Rd.,              |
| Beltsville, MD       | Research, Food and Drug Administration, 5901B Ammendale Rd., Beltsville, MD  20705.                                              |
| Surveillance, Office | sent to: Division of Compliance Risk Management and Surveillance, Office of Compliance, Center for Drug Evaluation and Research, |
| Research             | Office of Compliance, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                |
| Research             | Advertising and Communication, Center for Drug Evaluation and Research , Food and Drug Administration, 5901-B Ammendale Rd.,     |
| Beltsville, MD       | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                        |
| Research, ATTN       | and Drug Administration, Center for Biologics Evaluation and Research, ATTN : Sample Custodian, 10903 New Hampshire Ave., Bldg.  |
| Rm                   | 75,  Rm .                                                                                                                        |
| G707                 | G707 , Silver Spring, MD 20993-0002.                                                                                             |
| Research, ATTN       | and Drug Administration, Center for Biologics Evaluation and Research, ATTN : Sample Custodian, c/o White Oak Radiation Safety   |
| Rm                   | 52-72,  Rm .                                                                                                                     |
| G406A                | G406A , Silver Spring, MD 20993-0002.                                                                                            |
| Obtain               | (e)  Obtain updated mailing address information for biological products regulated                                                |
| Health               | (b) Secretary means the Secretary of  Health and Human Services and any other officer or                                         |
| Health               | (b) Secretary means the Secretary of  Health and Human Services and any other officer or                                         |
| Food                 | (c) Commissioner of  Food  and Drugs means the Commissioner of the                                                               |
| Columbia             | State means a State or the District of Columbia , Puerto Rico, or the Virgin Islands.                                            |
| Purity               | Purity includes but is not limited to relative freedom                                                                           |
| Casual               | Casual visitors shall be excluded from such units at                                                                             |
| Street               | Street clothing, including shoes, shall be replaced or covered                                                                   |
| Physical             | Physical  establishment, equipment, animals, and care.                                                                           |
| Work                 | Work  rooms shall be well lighted and ventilated.                                                                                |
| Apparatus            | Apparatus for sterilizing equipment and the method of operation                                                                  |
| Animal               | Animal quarters, stables and food storage areas shall be                                                                         |
| Laboratory           | Laboratory procedures of a clinical diagnostic nature involving materials                                                        |
| Environmental        | Environmental monitoring specific for the spore-forming microorganism(s) must be                                                 |
| Live                 | Live vaccine processing must be performed under appropriate controls                                                             |
| Appropriate          | Appropriate controls must include, at a minimum: (i)(A) Using                                                                    |
| Process              | Process containment is deemed to be necessary unless procedural                                                                  |
| Process              | Process containment is a system designed to mechanically isolate                                                                 |
| Written              | Written procedures must be in place for verification that                                                                        |
| Equipment            | Equipment and supplies used in work on or otherwise                                                                              |
| Animal               | Animal quarters and cages shall be kept in sanitary                                                                              |
| Due                  | Due precaution shall be taken to prevent cross-infection from                                                                    |
| Cage                 | Cage  mates shall not be interchanged.                                                                                           |
| Viable               | Viable antigens, when so used, shall be free of                                                                                  |
| Blood                | Blood shall not be used if it was drawn                                                                                          |
| Research             | notify the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and               |
| Research             | by the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                   |
| Research             | The Director, Center for Biologics Evaluation and  Research  or the Director, Center for Drug Evaluation and                     |
| Retention            | Retention  samples.                                                                                                              |
| Plasma               | Whole Blood, Cryoprecipitated AHF, Platelets, Red Blood Cells, Plasma , and Source                                               |
| Research             | submitted to the Center for Biologics Evaluation and Research  or the Center for Drug Evaluation and                             |
| Research             | by the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                   |
| Research             | regulated by the Center for Biologics Evaluation and Research (CBER), send the completed Form FDA 3486 to                        |
| Research             | regulated by the Center for Drug Evaluation and Research (CDER), send the completed Form FDA-3486 to the                         |
| Surveillance         | to the Division of Compliance Risk Management and Surveillance  (HFD-330) (see mailing addresses in &#167;&#8201;600.2).         |
| Food                 | shall be made by an officer of the Food and Drug Administration having special knowledge of the                                  |
| Health               | officer, agent, or employee of the Department of Health and Human Services specifically designated for such purpose              |
| Obtain               | observation of these procedures in actual operation, (e) Obtain and cause to be sent to the Director,                            |
| Research             | to the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                   |
| Adverse              | Adverse  experience.                                                                                                             |
| Disability           | Disability .                                                                                                                     |
| Individual           | Individual  case safety report (ICSR).                                                                                           |
| Serious              | Serious  adverse experience.                                                                                                     |
| Important            | Important medical events that may not result in death,                                                                           |
| Unexpected           | Unexpected adverse experience: Any adverse experience that is not                                                                |
| Unexpected           | &#8220; Unexpected ,&#8221; as used in this definition, refers to                                                                |
| Followup             | Followup information to adverse experiences submitted in a periodic                                                              |
| ICSRs                | ICSRs  must only be submitted to FDA once.                                                                                       |
| Unique               | an initial report or followup report; and (viii) Unique case identification number, which must be the same                       |
| Vaccine              | (4)  Vaccine (s) administered in the 4 weeks prior to                                                                            |
| Manufacturer         | (i) Name of vaccine;                                                                                                             |
|                      |               (ii)  Manufacturer ; (iii) Lot number; (iv) Route or site                                                          |
| Unique               | an initial report or followup report; and (viii) Unique case identification number, which must be the same                       |
| Distribution         | Distribution  reports.                                                                                                           |
| Research             | submit to the Center for Biologics Evaluation and Research  or the Center for Drug Evaluation and                                |
| United States        | in supply of that biological product in the United States if: (i) The biological product is life supporting,                     |
| United States        | disruption in supply of that product in the United States if: (i) The product is life supporting, life                           |
| U.S                  | a manufacturer of a significant percentage of the U.S . blood supply.                                                            |
| Biological           | Biological product shortage or shortage means a period of                                                                        |
| United States        | projected demand for the biological product within the United States  exceeds the supply of the biological product.              |
| Life                 | Life supporting or life sustaining means a biological product                                                                    |
| Significant          | Significant disruption means a change in production that is                                                                      |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1944-07-01 | 682), approved July 1, 1944.                                                                                                                                                                                                                                                                                                                                                                      |
| 136-09-20  | For vaccine adverse experience reports, these data will become part of the CDC Privacy Act System 09-20-0136, &#8220;Epidemiologic Studies and Surveillance of Disease Problems.&#8221; Information identifying the person who received the vaccine or that person's legal representative will not be made available to the public, but may be available to the vaccinee or legal representative. |


